CBT
ALXN

Capital Bank & Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

Capital Bank & Trust’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-44
Closed -$4K – 869
2019
Q3 		$4K Sell
44
-225
-84% -$25.4K ﹤0.01% 651
2019
Q2 		$35K Buy
269
+210
+356% +$27.1K ﹤0.01% 463
2019
Q1 		$8K Buy
+59
New +$7.34K ﹤0.01% 557
2018
Q4 		– Sell
-326
Closed -$45K – 878
2018
Q3 		$45K Buy
+326
New +$40.9K ﹤0.01% 470
2018
Q1 		– Sell
-71
Closed -$8K – 711
2017
Q4 		$8K Sell
71
-66
-48% -$8.04K ﹤0.01% 573
2017
Q3 		$19K Buy
137
+87
+174% +$11.8K ﹤0.01% 459
2017
Q2 		$6K Buy
+50
New +$5.82K ﹤0.01% 496

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Capital Bank & Trust's ALXN Position: Q4 2019 in Review

Capital Bank & Trust sold out of Alexion Pharmaceuticals (ALXN) in Q4 2019, closing a stake of 44 shares — an estimated $4K sold.

Capital Bank & Trust first reported a position in ALXN in Q2 2017 and held it in 7 quarters. The position peaked at $45K in Q3 2018. 669 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

  • Capital Bank & Trust reported no remaining Alexion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Capital Bank & Trust sold 44 Alexion Pharmaceuticals shares in Q4 2019, an estimated $4K.
  • Capital Bank & Trust first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 7 quarters.
  • Capital Bank & Trust's Alexion Pharmaceuticals position peaked at $45K in Q3 2018.
  • 669 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Capital Bank & Trust's 13F filing for Q4 2019, filed 18 Feb 2020.